Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Revenue of Pharvaris N.V. (PHVS)
Revenue in 2023 (TTM): $
According to Pharvaris N.V.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Pharvaris N.V.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-252,271 | $-96,853,839 | $-99,826,262 | $-100,875,000 |
| 2022 | $ | $-150,186 | $-86,584,816 | $-75,653,470 | $-76,332,557 |
| 2021 | $ | $-80,456 | $-54,061,256 | $-42,660,662 | $-42,730,779 |
| 2020 | $ | $ | $-25,005,399 | $-26,068,955 | $-25,985,704 |
| 2019 | $ | $-547 | $-8,009,732 | $-8,027,162 | $-8,044,043 |
| 2018 | $ | $ | $-4,313,534 | $-4,313,914 | $-4,314,294 |